share_log

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.

T2 Biosystems | 4：持股变动声明-股东 CR Group L.P.
美股sec公告 ·  05/07 17:03
Moomoo AI 已提取核心信息
CR Group L.P. has reported a series of acquisitions of common stock in T2 Biosystems, Inc. [TTOO], according to a filing dated 05/03/2024. The transactions were made indirectly through various entities associated with CR Group L.P. A total of 648,139 shares were acquired by CRG Partners III L.P., 403,608 shares by CRG Partners III - Parallel Fund (A) L.P., 129,629 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,565,445 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 2,001,514 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions were classified under the transaction code 'A', indicating a grant, award, or other acquisition of securities. Following these transactions, the total number of shares held by CR Group L.P. in T2 Biosystems stands at 8,853,173. The nature of the indirect beneficial ownership is specified for each entity involved in the acquisitions.
CR Group L.P. has reported a series of acquisitions of common stock in T2 Biosystems, Inc. [TTOO], according to a filing dated 05/03/2024. The transactions were made indirectly through various entities associated with CR Group L.P. A total of 648,139 shares were acquired by CRG Partners III L.P., 403,608 shares by CRG Partners III - Parallel Fund (A) L.P., 129,629 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,565,445 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 2,001,514 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions were classified under the transaction code 'A', indicating a grant, award, or other acquisition of securities. Following these transactions, the total number of shares held by CR Group L.P. in T2 Biosystems stands at 8,853,173. The nature of the indirect beneficial ownership is specified for each entity involved in the acquisitions.
根据2024年3月5日的一份文件，CR集团有限责任公司报告了一系列收购T2 Biosystems, Inc. [TTOO] 普通股。这些交易是通过与CR集团有限责任公司相关的多个实体间接进行的。CRG Partners III L.P. 共收购了648,139股股票，CRG Partners III——平行基金（A）L.P. 收购了403,608股股票，CRG Partners III（开曼）Unlev I L.P. 收购了129,629股股票，CRG Partners III（开曼）AIV I L.P. 共收购了1,565,445股股票 L.P.，以及CRG Partners III——平行...展开全部
根据2024年3月5日的一份文件，CR集团有限责任公司报告了一系列收购T2 Biosystems, Inc. [TTOO] 普通股。这些交易是通过与CR集团有限责任公司相关的多个实体间接进行的。CRG Partners III L.P. 共收购了648,139股股票，CRG Partners III——平行基金（A）L.P. 收购了403,608股股票，CRG Partners III（开曼）Unlev I L.P. 收购了129,629股股票，CRG Partners III（开曼）AIV I L.P. 共收购了1,565,445股股票 L.P.，以及CRG Partners III——平行基金B（开曼）有限责任公司发行的2,001,514股股票。这些收购被归类为交易代码 “A”，表示对证券的授予、奖励或其他收购。这些交易完成后，CR集团有限责任公司在T2 Biosystems持有的股份总数为8,853,173股。对于参与收购的每个实体，都规定了间接受益所有权的性质。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息